A Study of RG1678 (RO4917838) in patients with sub-optimally controlled symptoms of schizophrenia.
- Conditions
- Schizophrenia
- Registration Number
- JPRN-jRCT2080221450
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 600
Adult patients, >/= 18 years of age
-Diagnosis of schizophrenia
-Clinical stability for 12 weeks prior to screening period
-Antipsychotic treatment stability for 8 weeks prior to screening period
-With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotic (treatment with a maximum of two antipsychotics)
-Has treatment resistant schizophrenia as judged by the treating physician OR have failed two trials
-Evidence that patient has clinically significant uncontrolled or unstable medical disorder (e.g. cardiovascular, renal hepatic, gastrointestinal, hematologic, immunological, neurological, endocrine, metabolic or pulmonary disease)
-Patient has anorexia or obesity (body mass index (BMI) <18.5 or >40, respectively)
-Diagnosis of mental retardation or severe organic brain syndromes
-In the investigator's judgment, a significant risk of suicide or violent behavior
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method